On 21 August 2026, Celltrion announced that it has launched Steqeyma®, biosimilar to Janssen’s Stelara® (ustekinumab), in an intravenous (IV) formulation in Japan.
Celltrion’s IV formulation of Steqeyma® was approved in Japan in April 2026, with the subcutaneous formulation launching in July 2025 following its March 2025 approval. Both formulations of Steqeyma® are approved in Japan for psoriasis and psoriatic arthritis, and the IV formulation is additionally approved for Crohn’s Disease.
Celltrion is one of a number of biosimilar competitors that have launched ustekinumab products in Japan, including, Alvotech/Fuji Pharma (May 2024), Biocon/Yoshindo (May 2025) and Samsung Bioepis (May 2026).